School of Medicine
Showing 81-100 of 177 Results
-
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
Michael Fischbein
Thelma and Henry Doelger Professor of Cardiovascular Surgery
Current Research and Scholarly InterestsMolecular and genetic mechanisms of aortic aneurysm/dissection development. Molecular mechanisms of aneurysm formation in Marfan Syndrome. Clinical research interests include thoracic aortic diseases (aneurysms, dissections).
-
Adina S. Fischer, MD, PhD
Assistant Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)
On Leave from 10/10/2022 To 10/09/2024BioDr. Fischer’s research focuses on characterizing risk and resilience factors in depression. She has been awarded an NIH Career Development Award (K23) and Klingenstein Foundation Fellowship in Adolescent Depression to build her program of clinical and translational research at Stanford. Dr. Fischer's program of clinical care focused on the delivery and teaching of evidence-based clinical interventions that enhance resilience, with a focus on addressing the unique stressors encountered in academia and academic medicine that may contribute to risk and resilience in mood and anxiety disorders.
Dr. Fischer’s translational program of research focuses on:
(1) Improving our understanding of protective biomarkers of resilience to depression
(2) Characterizing the effects of cannabis on neurobiological function and depressive symptoms
(3) Developing neurobiologically-guided interventions for depressive disorders, particularly those that co-occur with cannabis and other substance use
Dr. Fischer earned her BSc at the Massachusetts Institute of Technology in Brain and Cognitive Sciences, where she conducted research in the Early Childhood Cognition Laboratory. She then completed the MD/PhD Program at Dartmouth, where she obtained her PhD in in Neuroscience. Dr. Fischer’s doctoral research focused on characterizing the acute effects of cannabis in patients with schizophrenia and co-occurring cannabis use disorder. She then completed the Stanford Psychiatry Residency Training Program as a member of the Research Track, and an NIH funded T-32 postdoctoral research fellowship within the Department of Psychiatry and Behavioral Sciences. -
Stephen Fischer
Associate Professor of Anesthesia at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsPreoperative evaluation of the medically complex, patient; cost-effectiveness of preop diagnostic testing; patient, outcome studies in relation to preoperative preparation; computer, database of patient perioperative data; development of the, Anesthesia Preoperative Clinic as a model of quality, efficient, and, cost-effective care.
-
Kevin Fish
Professor of Anesthesia at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsNeurological dysfunction after cardiopulmonary bypass;, metabolism of inhalation anesthetics.
-
Ann Caroline Fisher, MD
Clinical Associate Professor, Ophthalmology
BioCaroline Fisher, MD, is a Clinical Associate Professor of Ophthalmology at Stanford University Hospital and Clinics. She specializes in cataract and glaucoma surgery, including minimally invasive glaucoma surgery.
She completed her undergraduate education at Stanford University, obtaining both a Bachelor of Science degree in Biology and a Bachelor of Arts degree in Spanish, with Departmental Honors. She earned her medical degree from Stanford University School of Medicine and then went on to her internship at the University of Pennsylvania Presbyterian Hospital. She completed her ophthalmology residency at NYU/ Manhattan Eye, Ear, Throat Hospital. She then returned to Stanford for her Glaucoma Fellowship.
Dr. Fisher is Director of the Stanford Belize Vision Clinic, dedicated to promoting eye health and care in Belize, and providing an international rotation for Stanford Ophthalmology Residents. She is also an Office of Faculty Development and Diversity Liaison and is currently one of the Stanford Network for Advancement and Promotion (SNAP) Cohort Leaders. Dr. Fisher is the Director of Diversity, Equity, and Inclusion for the Department of Ophthalmology. -
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.
-
Robert Fisher, MD, PhD
The Maslah Saul, MD, Professor and Professor, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsDr. Fisher is interested in clincal, laboratory and translational aspects of epilepsy research. Prior work has included: electrical deep brain stimulation for epilepsy, studied in laboratory models and clinical trials; drug delivery to a seizure focus; mechanisms of absence epilepsy studied with in vitro slices of brain thalamus; hyperthermic seizures; diagnosis and treatment of non-epileptic seizures, the post-ictal state; driving and epilepsy; new antiepileptic drugs; surgery for epilepsy.
-
Matthew Fitzgerald, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsMy research encompasses several translational projects. One focus is to modify the routine audiologic test battery such that it places equal weight on hearing acuity and hearing function. This work includes measures of speech in noise, or electrophysiologic responses such as the FFR. I also explore tools to better assess and maximize performance in users of hearing aids and cochlear implants. Finally, I am also investigating the benefits of telemedicine, and new treatments for tinnitus.
-
Peter Fitzgerald, MD, PhD
Professor (Research) of Medicine (Cardiovascular), Emeritus
BioDr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering (by courtesy) at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 175 clinical trials, published over 550 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.
Dr. Fitzgerald has been principle/founder of twenty-one medical device companies in the San Francisco Bay Area. He has transitioned fourteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded TriVentures, which is an incubator/venture fund for early stage medical technology in Israel. -
Caroline Fleck
Adjunct Clinical Instructor, Psychiatry and Behavioral Sciences
BioDr. Caroline Fleck received her doctorate in Psychology & Neuroscience from Duke University, and went on to specialize in cognitive behavioral therapies including Exposure and Response Prevention, Dialectical Behavior Therapy, Parent Management Training, Gottman Method Couples Therapy, and Behavioral Activation. She is the founder and clinical director of Luma - a network of evidence-based clinicians in private practice. Dr. Fleck is also a trainer, educator, and public speaker on the topics of evidence-based approaches in psychology, mindfulness, and the use of technology in mental health care. Her lectures and courses at Stanford focus on training residents, post-docs, and faculty in Dialectical Behavior Therapy, and risk management.
More information can be found on her website: https://www.drcarolinefleck.com/ -
Dominik Fleischmann
Professor of Radiology (Cardiovascular Imaging)
Current Research and Scholarly InterestsNon-invasive Cardiovascular Imaging
Image Post-processing
Contrast Medium Dynamics -
Barry Fleisher
Associate Professor of Pediatrics at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsNeonatology, neurobehavioral development, outcomes in premature infants.
